



## **Cesca Therapeutics Inc. to Participate in the LD Micro 10th Annual Main Event on Thursday, December 7, 2017**

November 30, 2017

RANCHO CORDOVA, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. ("Cesca") (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Joe Balagot, senior vice president of corporate development, will be presenting at the LD Micro 10<sup>th</sup> Annual Main Event on Thursday, December 7 at 8:30am PST. The conference is being held December 5 – 7, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles.

A live webcast of the presentation will be available at <http://wsw.com/webcast/ldmicro13/kool>. The webcast will be archived for 90 days.

### **About Cesca Therapeutics Inc.**

Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.

### **Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Cesca's current expectations concerning future events and results. Forward-looking statements based on Cesca's current assumptions, expectations and beliefs are generally identifiable by use of words "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," or similar expressions and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those risk factors discussed in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") as well as other documents that may be filed by Cesca from time to time with the SEC, which are available at [www.sec.gov](http://www.sec.gov). We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

### **Company Contact:**

Cesca Therapeutics Inc.  
Wendy Samford  
916-858-5191  
[ir@cescatherapeutics.com](mailto:ir@cescatherapeutics.com)

### **Investor Contact:**

Rx Communications  
Paula Schwartz  
917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

Source: Cesca Therapeutics Inc.